EL7.AI
StocksUpdated×4•Originally published 27 April 2026•Updated 29 April 2026•
1 min read

Biogen Beats Q1 Estimates but Lowers Annual Profit Forecast on Acquisition Charges

Key Facts

1Truist Securities reiterated a Hold rating on Biogen Inc. with a $189.00 price target.
2BIIB080 Phase 2 CELIA data is expected by mid-year, which could validate the tau hypothesis in Alzheimer's.
3The stock has seen a 55% return over the past year, and InvestingPro suggests it is undervalued.

Biogen Inc. reported robust first-quarter results with revenue reaching $2.48 billion, driven by a surge in Leqembi sales, despite lowering its 2026 profit forecast due to acquisition charges. In parallel, PPG reported Q1 results where earnings per share matched analyst estimates, while revenues exceeded expectations bolstered by favorable currency gains. Unlike Biogen, PPG reaffirmed its full-year 2026 earnings guidance, maintaining its outlook despite the headwind of rising operational costs. Investors continue to monitor Biogen's upcoming Phase 2 CELIA data for BIIB080 as a critical mid-year milestone. Overall, market sentiment remains balanced as analysts weigh strong operational performance against long-term growth trajectories and cost pressures across these sectors.